PDS Biotechnology Appoints Dr. Ilian Iliev to Board of Directors
09 April 2020 - 10:30PM
PDS Biotechnology Corporation (“PDS Biotechnology”) (Nasdaq: PDSB),
a clinical-stage immuno-oncology company developing multiple
therapies based on T-cell activating technology called Versamune®
today announced that it has appointed Ilian Iliev, Ph.D. to its
Board of Directors.
“We are very pleased to welcome Dr. Iliev to the
Board of Directors. He brings a wealth of experience to PDS Biotech
as a recognized entrepreneur and venture capitalist across multiple
industries, including healthcare,” commented Steve Glover, Chairman
of the Board of PDS Biotech. “Together, we will help guide PDS
Biotech through its near and long-term milestones as we advance our
programs in infectious disease and immuno-oncology with leading
research institutions and pharmaceutical companies.”
Currently, Dr. Iliev is a Managing Director of
EMV Capital, a London-based investor in B2B companies in the
healthcare, transportation, energy and technology sectors.
Previously he founded CambridgeIP, a boutique consultancy focused
on IP commercialization based out of Cambridge, UK and working with
clients in healthcare, energy and other sectors. Dr. Iliev is a
Board Member of NetScientific PLC, a transatlantic healthcare IP
commercialization group that funds and develops companies that are
working to significantly improve the health and well-being of
people with chronic diseases. He also serves on the Board of
Directors of Sofant Technologies, Pointgrab, Q-Bot, Glycotest,
Vortex Biosciences and Wanda Health.
Dr. Iliev holds a Ph.D. from Cambridge
University’s Judge Business School, focused on Venture Capital
business models in emerging economies. He also received a Master of
Commerce in Economics, and Bachelor of Arts in Politics, Economics
and International Relations from the University of Witwatersrand.
He has published widely on entrepreneurship, venture capital, and
market trends in healthcare and energy and is an Associate Fellow
at the Royal Institute of International Affairs
About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy
company with a growing pipeline of infectious disease vaccines and
cancer immunotherapy based on the Company’s proprietary Versamune®
T-cell activating technology platform. The Versamune® platform
effectively delivers disease-specific antigens for in vivo uptake
and processing, while also activating a critical immunological
pathway, the type 1 interferon pathway, thus resulting in the
production of both neutralizing antibodies and potent
disease-specific killer T-cells. Using Versamune®, PDS Biotech is
engineering therapies designed to better recognize disease cells to
effectively attack and destroy them. PDS Biotech’s pipeline
combines the Versamune® technology with disease-specific antigens
across several therapeutic areas. To learn more, please visit
www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.
Forward Looking Statements
This communication contains forward-looking
statements (including within the meaning of Section 21E of the
United States Securities Exchange Act of 1934, as amended, and
Section 27A of the United States Securities Act of 1933, as
amended) concerning PDS Biotechnology Corporation (the “Company”)
and other matters. These statements may discuss goals, intentions
and expectations as to future plans, trends, events, results of
operations or financial condition, or otherwise, based on current
beliefs of the Company’s management, as well as assumptions made
by, and information currently available to, management.
Forward-looking statements generally include statements that are
predictive in nature and depend upon or refer to future events or
conditions, and include words such as “may,” “will,” “should,”
“would,” “expect,” “anticipate,” “plan,”
“likely,” “believe,” “estimate,” “project,” “intend,” and
other similar expressions among others. Statements that are not
historical facts are forward-looking statements. Forward-looking
statements are based on current beliefs and assumptions that are
subject to risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various
factors, including, without limitation:; the Company’s ability to
protect its intellectual property rights; potential adverse
reactions or changes to business relationships resulting from the
resignation of the Company’s Chief Financial Officer or the
Company’s ability to find a replacement Chief Financial Officer the
Company’s anticipated capital requirements, including the Company’s
anticipated cash runway and the Company’s current expectations
regarding its plans for future equity financings; the timing for
the Company or its partners to initiate the planned clinical trials
for its lead assets, PDS0101 and PDS0102; the Company’s
interpretation of the results of its Phase 1 trial for PDS0101 and
whether such results are sufficient to support additional trials or
the future success of such trials; the successful
implementation of the Company’s research and development programs
and collaborations, including any collaboration studies concerning
PDS0101 and the Company’s interpretation of the results and
findings of such programs and collaborations and whether such
results are sufficient to support the future success of the
Company’s product candidates; the acceptance by the market of the
Company’s product candidates, if approved; the timing of and
the Company’s ability to obtain and maintain U.S. Food and
Drug Administration or other regulatory authority approval of,
or other action with respect to, the Company’s product
candidates; and other factors, including legislative,
regulatory, political and economic developments not within the
Company’s control, including unforeseen circumstances or other
disruptions to normal business operations arising from or related
to COVID-19. The foregoing review of important factors that could
cause actual events to differ from expectations should not be
construed as exhaustive and should be read in conjunction with
statements that are included herein and elsewhere, including the
risk factors included in the Company’s annual and periodic reports
filed with the SEC. The forward-looking statements are made only as
of the date of this press release and, except as required by
applicable law, the Company undertakes no obligation to revise or
update any forward-looking statement, or to make any other
forward-looking statements, whether as a result of new information,
future events or otherwise.
Media & Investor Relations
Contact:
Deanne RandolphPDS BiotechPhone: +1 (908)
517-3613Email: drandolph@pdsbiotech.com
Tram Bui / Alexander LoboThe Ruth GroupPhone: +1
(646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com /
alobo@theruthgroup.com
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2024 to May 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From May 2023 to May 2024